Public health impact of the adjuvanted RSVPreF3 vaccine in adults aged 60 years and older: results from a modeling study in six Latin America countries

Public health impact of the adjuvanted RSVPreF3 vaccine in adults aged 60 years and older: results from a modeling study in six Latin America countries

Background Respiratory syncytial virus (RSV) can cause acute respiratory infection (ARI) and severe symptoms in older adults. The adjuvanted RSV prefusion F protein vaccine (adjuvanted RSVPreF3) offers protection to adults against RSV ARI and RSV lower respiratory tract disease (LRTD). We modeled th...

Full description

Saved in:
Bibliographic Details
Main Authors: Ru Han, Jorge A Gomez, Nancy Bellei, Otavio Cintra, Bruna M G de Veras, Desirée van Oorschot, Adriana Guzman-Holst
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Expert Review of Vaccines
Subjects:
Adjuvanted RSVPreF3 vaccine
latin America
Markov model
public health impact
RSV
Online Access:https://www.tandfonline.com/doi/10.1080/14760584.2025.2539892
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

https://www.tandfonline.com/doi/10.1080/14760584.2025.2539892

Similar Items